We are committed to building a comprehensive product portfolio mainly targeting two markets with large unmet demands, namely vascular intervention, and NOTES.
We have been concurrently developing cryotherapy systems for treating atrial fibrillation, hypertension, asthma, chronic obstructive pulmonary disease , airway stenosis, ladder cancer, gastric cancer, esophageal cancer and other diseases. In parallel we have developed non-cryotherapy products including our anti-gastroesophageal reflux system. Furthermore, we have successfully commercialized products such as the pulmonary nodule localization needle, laparoscopic single-port multi-channel access platform, bladder cryoablation system and endoscopic clip for anastomosis.
• Invest in vascular intervention to develop innovative cryoablation systems for treatments of major cardiovascular diseases.
• Provide clinical solutions to fulfill a variety of unmet clinical needs through NOTES.